Ai-BrainScience Inc., (Office; Osaka, CEO: Kentaro Takamura Ph.D., “Ai-BrainScience” hereof) announce that the company is awarded a Prize for the Award for Academic Startups  program 2022 in Japan, the joint-program sponsored by Japan Science and Technology Agency (Japan’s government agency under the Ministry of Education, Culture, Sports, Sciences and Technology, abbreviated as “JST”), and New Energy and Industrial Technology Development Organization (Japan’s government organization under the Ministry of Economy, Trade and Industry, abbreviated as “NEDO”).

This prize covers two entities as supporter: Clinical Gene Therapy, Graduate School of Medicine, Osaka University (Associate Prof. Shuko Takeda, Principal Investigator) and Future Corporation (Mr. Atsushi Nakamoto, Vice President, AI & Healthcare Leader).

Background of Award

JST and NEDO evaluate that the eye-tracking cognitive assessment (‘ETCA’) that Ai-BrainScience develop can contribute to early diagnosis for dementia including potential cognitive decline. Also, the early intervention and treatment after early diagnosis have a clinical and social positive impact. The technology can be a global application as the demand of requiring diagnosis is increasing around the world.

Outline of Award for Academic Startups program

JST and NEDO have hosted the Award for Academic Startups since 2014. This program aims to promote the establishment of businesses that makes use of R&D outcomes achieved by universities or other entities and encourage startups and universities to innovate further.

Homepage of the Award for Academic Startups

https://www.jst.go.jp/aas/award.html (in Japanese only)